Innate Pharma has signed a co-development and commercialization agreement with AstraZeneca and MedImmune, AstraZeneca’s wholly-owned subsidiary. The deal focuses on the development of anti-NKG2A antibody, IPH2201, also in combination with MEDI4736, an anti-PD-L1 immune checkpoint inhibitor created by MedImmune, to fight cancer. The compound IPH2201 currently is in Phase II development.
Under the terms of the arrangement, AstraZeneca will make cash payments up to $1.275 billion to Innate, as well as “double digit royalties on sales,” according to BioSpace.com. The down payment is $250 million. The deal also provides AstraZeneca exclusive global rights to co-develop and commercialize IPH2201 with MEDI4736, as well as frees the company up to work with IPH2201 in monotherapy and in other combinations.
Prior to the start of Phase III development, AstraZeneca will pay Innate another $100 million, BioSpace.com notes. Another $925 million is possible if regulatory and sales-related milestones are met. Innate keeps the rights to co-promote in Europe for 50 percent of the profits.